THE US Food and Drug
Administration has withdrawn
its approval for indications of co-administration
of statins with niacin
and fenofibric acid, which will see
the removal from the US market of
Abbvie’s Advicor and Simcor, along
with Niaspan and Trilipix and their
generic equivalents.
The FDA said “the totality of the
evidence no longer supports the
conclusion that a drug-induced
reduction in triglycideride levels
and/or increase in HDL cholesterol
levels in statin-treated patients
results in a reduction in the risk of
cardiovascular events”.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Apr 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.